T1046 Quality of Life After Adjuvant Intra-Arterial Chemotherapy and Radiotherapy Versus Surgery Alone in Resectable Pancreatic and Periampullary Cancer. A Prospective Randomized Controlled Study

Department of Surgery, Erasmus Medical Centre, 3015 CE Rotterdam, The Netherlands.
Cancer (Impact Factor: 4.89). 02/2010; 116(4):830-6. DOI: 10.1002/cncr.24809
Source: PubMed


Adjuvant therapies for pancreatic and periampullary cancer reportedly achieve only a marginal survival benefit. In this randomized controlled trial, 120 patients with resected pancreatic or periampullary cancer received either adjuvant celiac axis infusion chemotherapy combined with radiotherapy (CAI/RT) or no adjuvant treatment. The objective of the study was to compare the quality of life (QoL) in patients who received CAI/RT after pancreatoduodenectomy with the QoL in patients who did not receive adjuvant treatment.
During and after CAI/RT, QoL was assessed using the European Organization for Research and Treatment of Cancer QoL Questionnaire C30 every 3 months during the first 24 months after randomization.
Eighty-six percent of patients (n = 103) completed 1 or more questionnaires. In total, 355 questionnaires were completed. The results indicated that CAI/RT did not impair physical, emotional, or social functioning. During and after CAI/RT, patients had significantly less pain (P = .02) and less nausea and vomiting (P = .01). Overall QoL (global functioning) tended to be better (P = .08) after CAI/RT.
Over a period of 24 months, CAI/RT improved QoL compared with observation alone in patients with resected pancreatic and periampullary cancer. This beneficial effect of CAI/RT was most prominent in the latter half of the follow-up.

Download full-text


Available from: Erwin J O Kompanje, Sep 01, 2014
  • Source
    • "Previous studies analyzed three main quality of life measurements (health status, functional status, symptoms) for patients with pancreatic cancer using the EORTC QLQ-C30 questionnaire.[12] [13] [14] Other studies have used similar scales (physical, social, psychological, emotional) when mailing a quality of life questionnaire to survivors of pancreatic cancer who had undergone pancreaticoduodenectomy.[9] [15] [16] In general, these studies demonstrated that quality of life was similar for patients after completion of treatment compared to patients without cancer. However, these studies were limited to long-term survivors, had small sample sizes, and excluded a large portion of patients who survive only a few months, when quality of life may be at its worst. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Little is known about resource utilization (number of days in the hospital or medical care) between diagnosis and death in patients with pancreatic cancer. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data, we identified 25,476 patients with pancreatic cancer (1992-2005). Hospital and medical care days per person-month from the time of diagnosis were described, stratified by stage, treatment, and survival duration. Hospital/medical care days vary by length of survival and treatment strategy in patients with pancreatic cancer. For all stages, patients were in the hospital a mean of 6.4 days and received medical care a total of 9.0 days in the first month after diagnosis, decreasing to 1.7 and 3.7 days per month, respectively, by the end of the first year. Hospital/medical care days per month of life were higher in patients with shorter survival but increased sharply at the end of life in all patients, regardless of duration of survival. In patients with locoregional disease, resection was associated with a higher number of hospital/medical care days during the first 4 months after diagnosis, but fewer at the end of the first year. For distant disease, hospital days were similar but days in medical care were higher for patients receiving chemotherapy, increasing especially at the end of life. This study is the first to quantify hospital/medical care days in patients with pancreatic cancer by stage, treatment, and survival. This information will provide realistic expectations and allow for treatment decisions based on patient preferences.
    Annals of Surgical Oncology 03/2012; 19(8):2435-42. DOI:10.1245/s10434-012-2326-2 · 3.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aufgrund der fehlenden Frühsymptome besteht bei ca. 60% der Patienten mit Pankreaskarzinom zum Zeitpunkt der Diagnosestellung bereits eine Fernmetastasierung bzw. ein lokal weit fortgeschrittenes Erkrankungsstadium (70%). Bereits bei der Diagnosestellung können mehr als 80% der Patienten nicht kurativ im Sinne einer mikroskopisch kompletten Resektion (R0) therapiert werden. Doch auch bei einer R0-Resektion besteht ein Risiko von 35–90% eines lokalen Rezidivs bzw. der hepatogenen oder peritonealen Fernmetastasierung (50–90%). Trotz des ständigen Fortschritts in der operativen Versorgung dieser Patienten besteht auch weiterhin eine Fünfjahresüberlebenswahrscheinlichkeit von weniger als 25% sowie ein medianes Überleben von 15Monaten nach einer R0-Resektion. Randomisierte Studien zeigten eine Verbesserung der medianen Überlebenszeit durch eine adjuvante Chemotherapie mit 5-Fluorouracil (5-FU) bzw. Gemcitabin auf 20–23Monate im Vergleich zur alleinigen operativen Versorgung. Auch bei Patienten in lokal fortgeschrittenen Stadien bzw. mit Fernmetastasen trägt eine palliative Chemotherapie zur Verbesserung des medianen Überlebens um ca. 1–2Monate bei. Bereits vor 10Jahren wurde 5-FU als Standardmedikament in der palliativen Therapie des Pankreaskarzinoms von Gemcitabin abgelöst. Ziel einer multimodalen Therapie sollte die Verbesserung der Resektabilität der Tumoren sowie die Erhöhung der Rate an kompletten Resektionen sein, um dadurch die lokale und systemische Kontrolle zu verbessern. Pancreatic cancer affects approximately 200,000 people every year worldwide and most of them die of the disease. There are no early symptoms therefore approximately 70% of patients have locally advanced disease or even distant metastases (60%) at the time of diagnosis. At this time more than 80% of the patients cannot be treated by a microscopically complete resection (R0). Even if a microscopically complete resection is achieved local recurrence of pancreatic carcinoma can be expected in 35–90% of patients. Hepatic and peritoneal metastases are expected in 50–90%. There have been great advances in surgical techniques but 5-year survival rates still remain at less than 25% and also median survival times are not longer than 15 months after microscopically complete resection. Randomized clinical trials have shown an additional improvement in median survival times of 20–23 months for adjuvant chemotherapy with 5-fluorouracil or gemcitabine compared to surgery alone. Palliative chemotherapy also extends the medial survival time of patients with distant metastases or locally advanced disease for 1–2 months. The standard of cytostatic therapy with 5-fluorouracil was replaced by gemcitabine 10 years ago. A concept of multimodal therapy is needed in order to increase the rate of complete resections as well as the possibility of surgery to get a better local and systemic control, therefore integration of radiotherapy in the treatment of pancreatic carcinoma seems to be necessary. How radiotherapy can contribute to a better prognosis of pancreatic carcinoma in a neoadjuvant, adjuvant and palliative situation in the context of these concepts is the main topic of this article. SchlüsselwörterPankreaskarzinom-Radiochemotherapie-Lokal fortgeschritten-Adjuvant-Neoadjuvant KeywordsPancreatic carcinoma-Chemoradiation treatment-Local advanced-Adjuvant-Neoadjuvant
    Der Onkologe 06/2010; 16(6):588-594. DOI:10.1007/s00761-010-1845-3 · 0.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite rapid advances in cancer diagnosis and treatment, pancreatic cancer remains one of the most difficult human malignancies to be treated, with a mortality rate nearly equal to its incidence. Although gemcitabine has been established as the standard first-line treatment for advanced pancreatic cancer, gemcitabine-based combination chemotherapy showed either marginal or no improvement in survival. Developments in liposomal delivery systems have facilitated the targeting of specific agents for cancer treatment. Such systems could be developed as platforms for future multi-functional theranostic nanodevices tailor-made for the combined detection of early cancer and functional drug delivery. We systemically review liposome based drug-delivery systems, which can provide improved pharmacokinetics, reduced side effects and potentially increased tumor uptake, for pancreatic cancer therapy. Novel liposomal formulations allowing for higher tumor targeting efficiencies and used in current clinical trials to treat this challenging disease are emphasized.
    Cancer Treatment Reviews 02/2011; 37(8):633-42. DOI:10.1016/j.ctrv.2011.01.006 · 7.59 Impact Factor
Show more